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Background. Asthma and obesity are common; however the impact of obesity upon asthma remains uncertain. Objectives.T o
assess relationships between obesity and fat mass with airway inﬂammation, lung function, and disease control in patients with
refractoryasthma.Methods.151refractoryasthmapatientswerecharacterisedformeasuresofairwayinﬂammation,lungfunction,
Juniper asthma control questionnaire (JACQ), body mass index (BMI), and fat mass index (FMI) derived from dual energy X-ray
absorptiometry. Patients were reassessed over 12 months. Results. 74% of patients had an elevated BMI. BMI and FMI correlated
(r = 0.9, P<. 001). FMI and JACQ correlated in men (r = 0.3, P = .01). After 12 months 23% lost weight. Weight change over
12months correlated with FEV1 change (r =− 0.3, P = .03), but not with change in JACQ or exacerbations. Conclusion. Increased
fat mass is common in refractory asthma and is associated with asthma symptom control in men. Loss of weight is associated with
improvement in lung function in refractory asthma.
1.Introduction
Asthma is common and increasing in prevalence, with an
estimated300millionsuﬀerersworldwide [1].Severeasthma
represents 5%–10% of asthma suﬀerers and is of particular
importance as in this group there is greater morbidity [2]
and mortality [3] and an increased burden upon health
care resources. Likewise, obesity is increasingly common
[4] and is a signiﬁcant health problem associated with
cardiovascular disease, diabetes mellitus and malignancy
[5, 6]. There is increasing recognition that severe asthma
is a heterogeneous condition; whilst there is an obese
predominately noneosinophilic phenotype [7]. Therefore it
remains a possibility that obesity may be an important factor
in a subgroup of asthmatics. To date studies of obesity in
asthma have focussed upon the body mass index (BMI),
although a criticism of the BMI is that it does not take
into account body composition. The dual energy X-ray
absorptiometry (DEXA) scan includes the measurement of
regional fat mass and therefore is a more reliable measure of
obesity than BMI [8].
Unsurprisingly these two common conditions often
coexist, but whether obesity is a major determinant of
asthma severity or whether weight reduction impacts on
asthma control or exacerbations remains uncertain. We
hypothesised that obesity is related to asthma control
and that change in weight over 1 year is associated with
asthma control and exacerbations. To test this hypothesis, we
undertook DEXA scans in patients with refractory asthma
and assessed clinical outcomes, including measures of airway
inﬂammation and symptom control with fat mass and body
mass. We collected data after 1 year and assessed weight
changes with respect to airway inﬂammation and asthma
symptom control.
2. Methods
2.1. Patients. Severe asthmatics attending the “diﬃcult
asthma clinic” at the Glenﬁeld Hospital, Leicester, UK, were
invited to enter the study. All patients fulﬁlled the American
Thoracic Society (ATS) criteria for refractory asthma [9].2 Journal of Allergy
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Figure 1: Correlation of fat mass index (FMI) and body mass index
(BMI) in refractory asthmatic patients.
Patients that had had a severe exacerbation requiring high
doseoralcorticosteroidsandorantibioticsinthelast6weeks
were excluded. The study was approved by the Leicestershire,
Northamptonshire and Rutland ethics committee, and all
patients gave informed written consent.
2.2. Measurements. All patients were assessed using a
standardised protocol. Patients underwent spirometry pre-
and postbronchodilation with 200μg salbutamol (Vitalo-
graph, UK), allergen skin prick testing for dermatophagoides
pteronyssinus, dog, cat, aspergillus, and grass pollen; total
IgE; sputum analysis [10], exhaled nitric oxide (measured
at 50ml/s; NIOX, Aerocrine, Sweden) and disease symptom
control assessed by the Juniper asthma control question-
naire (JACQ) [11]. JACQ is a standardised questionnaire
composing of 7 questions where responses range in score
from 0 to 6; 0 is complete control, and 6 is uncontrolled
asthma symptoms, including a score for prebronchodilator
forced expiratory volume in 1 second (FEV1). An average
JACQ score of >1.5 is considered to represent poor asthma
symptom control [12]. Body habitus was assessed using the
body mass index (BMI) [13] and detailed body composition
by dual energy X-ray absorptiometry (DEXA scan) (Lunar
Prodigy, USA). Fat mass (FM) and fat-free mass (FFM)
were analysed from the DEXA scan and were corrected for
body surface area to derive the fat mass index (FMI) and
fat-free mass index (FFMI). Patients were followed for one
year with repeated measures of airway inﬂammation, lung
function, asthma symptom control, and weight. FMI gender
diﬀerences occur, and there is limited data on normal ranges
[8]; we thus chose ap r i o r ito divide each gender group into
tertilesbasedupontheirFMIandassesschangeswithinthese
groups.
2.3. Statistical Analysis. Statistical analysis was performed
using PRISM version 5 (GraphPad, San Diego, CA) and
SPSS version 16 (SPSS, Inc., Chicago, IL). Parametric data
was expressed as mean (SEM), and nonparametric data
is expressed as median (IQR). Log-transformed data is
presented as geometric mean (95% conﬁdence interval).
Correlation was measured using the Pearson correlation (r)
or Spearman rank correlation (rs)c o e ﬃcients for parametric
and non-parametric data. The coeﬃcient of determination
(R2) is presented where appropriate. For comparison of
unpaired or paired parametric or nonparametric groups,
the Student is t-test, Paired t-test, Mann-Whitney test, and
Wilcoxon matched pairs test were used, respectively. For
comparison of three groups or more for parametric and
nonparametric variables, the one-way analysis of variance
(ANOVA) or Kruskal-Wallis test was used and the χ2 test
for proportions. Signiﬁcant weight change after 1 year was
deﬁned as ±2kg [14]. Multiple regression was used to
assess the relationship of the dependant variable change in
asthma symptom control with explanatory (independent)
variables using the standard enter method. The independent
variables entered into the regression model chosen for
clinical relevance were the following continuous variables:
(i) change in postbronchodilator FEV1% predicted; (ii)
change in weight; (iii) change in inhaled corticosteroid
dose; (iv) change in sputum eosinophils (log transformed).
Collinearity diagnostics were performed and determined
that the model showed no violation of multicollinerarity or
homoscedasticity, and the residuals observed normality [15].
A P value of <.05 was deemed statistically signiﬁcant.
3. Results
151 patients (69 men, 82 women) were entered into the
study. Using age- and gender-speciﬁc normal ranges [8],
we estimated that FMI were increased in 75% of men and
79% of women. FMI and BMI was strongly correlated (r =
0.91, P<.0001, Figure 1). 2% of patients were underweight
(BMI < 18.5), 23% had normal weight (18.5 ≤ BMI < 25),
31% were overweight (25 ≤ BMI < 30), and 44% were
obese (BMI ≥ 30). The clinical characteristics for all patients
categorised into tertiles based on their baseline FMI are
outlined in Table 1.
We found no diﬀerence in BMI, JACQ score or pattern
of airway inﬂammation between men and women. Men had
a lower percentage predicted forced expiratory volume in
1s e c o n d( F E V 1) than women (mean diﬀerence (95% CI)
8.1% (1.2 to 15.1); P = . 0 2 )a n da i r ﬂ o wo b s t r u c t i o n( m e a n
(SEM) FEV1/FVC% 67 (2) versus 74 (1), P< .001). For
all patients, there was no correlation between FMI or BMI
and exacerbation frequency (r = 0.05, P = .59; r = −0.01,
P = .88), post-bronchodilator FEV1% predicted (r = 0.02,
P = .88; r = −0.01, P = .91), neutrophilic (r = −0.02, P = .84;
r = 0.01, P = .92) or eosinophilic airway inﬂammation (rs =
0.11, P = .22; rs = 0.08, P = .34). There was a statistically
signiﬁcant albeit weak, correlation of FMI and JACQ score
(r = 0.17, P = .04); this relationship was observed in men but
notwomen(r =0.34,P = .005;r = −0.01,P = .93).Therewas
no correlation between JACQ and BMI (r = 0.15, P = .06).
After stratiﬁcation into tertiles, subgroup analysis of men
and women revealed that men had a signiﬁcant diﬀerence
in JACQ score between the FMI tertiles (ANOVA JACQJournal of Allergy 3
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Figure 2: Juniper asthma control questionnaire (JACQ) score after tertile stratiﬁcation of fat mass index (FMI) for men (top) and women
(bottom). Horizontal bars set at mean and standard error of the mean.
and JACQindependent of FEV P<.001, P = .01 Figure 2). Linear
regression across the tertiles was also signiﬁcant (r = 0.33;
P = .005). This diﬀerence between tertiles was not evident in
women (Figure 2).
One year follow-up clinic visits with measurement of
weight and JACQ scores was available in 129 patients; 8
patients were discharged from clinic, 13 patients were lost to
followup,and1patientdied.77%ofpatientshadachangein
weight of ±2kg. 54% of patients had a mean (SD) increase
in weight of 4.9 (2.9)kg, and 23% of patients had a mean
(SD) decrease in weight 4.4 (2.8)kg. At baseline there were
no diﬀerences between men and women that subsequently
gained, lost or did not have a change in weight. Compared
to baseline there was no diﬀerence after 1-year follow-
up in lung function, maintenance corticosteroid, inhaled
corticosteroid dosage, JACQ scores, or eosinophilic airway
inﬂammation in men or women that lost weight, gained
weight, or did not change their weight (Tables 2 and 3).
Change in weight correlated with change in FEV1,b u t
not change in symptoms or exacerbations (r = −0.3, P = .03;
r = −0.02, P = .84; r = 0.01, P = .94, resp.) (Figure 3); this
correlation was evident in women and not men (r = −0.34,
P = .01 versus r = 0.14, P = .31). In men but not women,
there was an association of change in FEV1 and change in
exacerbations and JACQ (men: r = −0.34, P = .01; r = −0.46,
P<.01 and women: r = −0.01, P = .97; r = −0.16, P = .20).
Multiple regression analysis showed that change in asthma
control symptoms after 1 year could not be determined by
changes in weight, eosinophilic airway inﬂammation, lung
function, or corticosteroid dosage (R2 = 0.10, P = .13).
4. Discussion
We report here for the ﬁrst time the body composition of
a cohort of patients with severe refractory asthma using the
DEXA scan. In this group we found that symptom control
as measured by the Juniper asthma control questionnaire
correlated with fat mass in men, but not women. Fat mass
was not associated with lung function, airway inﬂammation,
or exacerbation frequency. Over a 1 year follow-up the
majority of patients with refractory asthma attending our
specialist asthma clinic gained weight, which was indepen-
dent of changes in treatment. There were no associations
between the change in weight and the change in asthma
control, airway inﬂammation or exacerbations. Interestingly,
in women that lost weight there was an improvement in lung
function, which was not observed in men.
The association of obesity and asthma has been evident
from epidemiological studies, including case control studies
and cross-sectional studies that have shown an increase
risk of asthma in obese individuals based on the BMI
[16–20], whilst longitudinal cohort studies have shown
an increase in asthma in obese patients, but these have
often been in self-reported asthma diagnosis [21, 22].
The association between asthma control and obesity is
contentious and reports present conﬂicting ﬁndings [23,
24] .T h e s eo b s e r v a t i o n sh a v ep r i m a r i l yf o c u s s e do nb o d y
mass index as a measure of obesity and more importantly
have not focussed on a severe refractory population. We
therefore have extended these earlier observations to report
for the ﬁrst time the fat mass, derived from DEXA scans, in
patients with refractory asthma. We found a cross-sectional
association between fat mass and asthma control in men
only.
We have previously identiﬁed a subphenotype of severe
asthmatics that were predominately obese non-eosinophilic
women [7]. However, we were unable to ﬁnd any cross-
sectional association between fat mass, airway inﬂammation,
and lung function; or between asthma control and fat mass
in women. Similarly, we did not ﬁnd a relationship between
obesity and atopy, which has been previously reported by
some [25], but not by others [26], suggesting that the cross-
sectional associations are complex.Journal of Allergy 5
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Figure 3: Scatter plot for change in weight versus change in postbronchodilator FEV1 (a), JACQ symptoms (b), and exacerbations (c).
A strength of our ﬁndings is that we assessed patients
over a 1 year follow-up period. This allowed us to examine
the longitudinal relationship between changes in weight
and clinical outcomes. Previous studies looking at morbid
obesity, mainly in women, and the eﬀect of weight loss
following bariatric surgery have shown improvement in
asthma control [27]. One-year follow-up of the TENOR
cohort of moderate to severe asthmatics found that in the
weight reduction group there was a small, albeit signiﬁcant,
attenuation in the exacerbation frequency [14], whilst others
have reported that severe exacerbations of asthma requiring
hospital admission were associated with longer hospital
stay in those with concomitant obesity [28]. Although
we did not ﬁnd any association between weight loss and
reductionsinexacerbationsorasthmacontrol,itdidimprove
lung function, the greatest magnitude found in women,
whilst independently in men there was a signal of lung
function improvements with asthma control and reduction
in exacerbations. Our data suggests that the cross-sectional
and longitudinal relationship between gender, obesity, and
asthma outcomes are distinct. Importantly, change in weight
was not associated with change in airway inﬂammation
or medication. It is possible that weight reduction may
reduce the burden on the workload of breathing and increase
exercise capacity with the observation of improvements in
lung function. The predilection for this improvement in
women only may suggest a diﬀerent fat loss distribution,
which may in turn lead to reduction in exacerbations, but
needs to be further evaluated. In this study we could not
determine a suitable model for change in asthma control
over 1 year with respect to change in weight, lung function,
and airway inﬂammation, suggesting that interactions of
symptom control in refractory asthma are indeed complex
with dissociation in some individuals [7].
One potential criticism of our study is that the follow-
up assessment did not include a repeat DEXA scan to assess
changes in body composition, but relied upon change in
weight. However, in this group we found that FMI and BMI8 Journal of Allergy
were very strongly correlated so we are conﬁdent that change
in weight was likely to be a consequence of a reduction
in fat mass. Although this was an observational study and
not a placebo-controlled intervention study, our ﬁndings do
support a possible association, albeit small between weight
reduction and improvements in asthma outcomes and may
pave the way for future trials of weight reduction in severe
refractory asthma. Importantly, future studies will need to
further explore the potential mechanisms of the association
between asthma control and obesity, which may have both
physical and psychological components.
Taken together this data demonstrates that the rela-
tionship between obesity and asthma outcomes in severe
refractory asthma is complex. We have identiﬁed cross-
sectional associations between asthma control and obesity
in men, and a longitudinal relationship between weight loss
and lung function improvements. These observations need
to be replicated in large intervention trials and highlight the
potential importance of comorbid obesity in severe asthma.
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